RegCell

Executive Summary

RegCell is a preclinical-stage biotechnology company pioneering regulatory T cell (Treg) therapies to restore immune tolerance in autoimmune diseases. Founded in 2019 and headquartered in Cambridge, MA, the company leverages foundational Treg biology to develop potentially curative treatments for rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. RegCell aims to move beyond symptom management by inducing durable immune tolerance, offering a transformative approach to chronic autoimmune conditions. The company is currently in Phase 1 clinical development for its lead candidate, RCT-01, targeting rheumatoid arthritis. Early data suggest a favorable safety profile and signs of immunological effect, positioning RegCell as a promising player in the cell therapy space. However, as an early-stage private company, it faces significant technical and regulatory hurdles, including manufacturing scalability, durability of response, and competition from established players. Key upcoming milestones include Phase 1 data readouts, potential strategic partnerships, and expansion into additional indications. With a focused pipeline and strong scientific foundation, RegCell represents a high-risk, high-reward opportunity in the autoimmune cell therapy landscape.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 clinical data readout for RCT-01 in rheumatoid arthritis60% success
• Q3 2026Strategic partnership for type 1 diabetes program50% success
• Q4 2026IND filing for multiple sclerosis indication70% success